for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nice Ltd (ADR)

NICE.OQ

Latest Trade

150.00USD

Change

1.56(+1.05%)

Volume

81,803

Today's Range

149.01

 - 

151.00

52 Week Range

102.69

 - 

161.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
148.44
Open
149.60
Volume
81,803
3M AVG Volume
4.96
Today's High
151.00
Today's Low
149.01
52 Week High
161.00
52 Week Low
102.69
Shares Out (MIL)
62.13
Market Cap (MIL)
9,051.33
Forward P/E
28.49
Dividend (Yield %)
--

Next Event

Q4 2019 Nice Ltd Earnings Release

Latest Developments

More

Nice Ltd Says Lake Corp Has Joined Devone Ecosystem Program

Nice Reports Q2 Non-GAAP Earnings Per Share Of $1.25

Volvere Announces Disposal Of Sira Defence And Security Limited

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Nice Ltd (ADR)

NICE Ltd., formerly NICE-Systems Ltd., is a global enterprise software provider. The Company's segments include Customer Interactions Solutions, and Financial Crime and Compliance Solutions. The Customer Interactions Solutions segment provides data driven insights that enable businesses to deliver personalized experience to customers. The Financial Crime and Compliance Solutions segment provides real time and cross-channel fraud prevention, anti-money laundering, brokerage compliance and enterprise-wide case management. The Company serves contact centers, back office operations and retail branches, covering various industries, including communications, banking, insurance, healthcare, business processes outsourcing (BPO), government, utilities, travel and entertainment. Its Multi-Channel Recording and Interaction Management enables organizations to capture structured and unstructured customer interaction and transaction data from multiple channels.

Industry

Software & Programming

Contact Info

13 Zarchin Street, P.O.B. 690

+972.9.7753777

https://www.nice.com

Executive Leadership

David Kostman

Independent Chairman of the Board

Barak Eilam

Chief Executive Officer

Beth Gaspich

Chief Financial Officer

Barry Graham Cooper

President, Enterprise Group

Craig Costigan

Chief Executive Officer, NICE Actimize

Key Stats

2.25 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.0K

2017

1.3K

2018

1.5K

2019(E)

1.6K
EPS (USD)

2016

3.610

2017

4.100

2018

4.690

2019(E)

5.265
Price To Earnings (TTM)
52.55
Price To Sales (TTM)
5.82
Price To Book (MRQ)
4.26
Price To Cash Flow (TTM)
25.49
Total Debt To Equity (MRQ)
21.16
LT Debt To Equity (MRQ)
21.16
Return on Investment (TTM)
6.87
Return on Equity (TTM)
5.55

Latest News

Latest News

Israel's Nice third quarter profit tops estimates, lifts 2019 profit outlook

Israeli software provider Nice <NICE.TA> reported a bigger-than-expected 8% increase in quarterly net profit, fueled by growth in its cloud platforms, and raised its outlook for full-year earnings.

Israel's Nice Q2 profit tops forecast, raises 2019 estimates

Israeli software provider Nice reported a bigger-than-expected 14% increase in quarterly net profit, fuelled by growth in its cloud platforms, and raised its guidance for the rest of the year.

Nice Systems' Q1 results top estimates, raises 2019 guidance

Israeli software provider Nice reported a higher-than-expected increase in quarterly net profit, driven by growth in cloud revenue, and raised its guidance for the rest of the year.

Nice Systems' record Q4 results top estimates, sees growth in 2019

Israeli software provider Nice reported a higher-than-expected rise in quarterly net profit and forecast continued growth in 2019, boosted by demand for its cloud and analytics tools.

Novartis's cancer therapy wins UK backing after initial lymphoma snub

Novartis's Kymriah cell therapy won the blessing of health authorities in England for adult lymphoma patients, the Swiss drugmaker said on Friday, reversing last year's rejection.

Cloud growth helps Israel software firm Nice beat Q3 estimates

Israeli software provider Nice reported a higher-than expected 18 percent rise in quarterly net profit, boosted by continued growth in its cloud and analytics tools.

UK rejects Gilead's CAR-T cancer cell therapy as too expensive

A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain's state-funded health service, the country's healthcare cost agency NICE said on Tuesday.

Israeli software provider Nice beats Q2 profit estimates

Israeli software provider Nice beat second-quarter profit forecasts on Thursday and raised its full-year earnings forecast by 3 cents a share, bolstered by its cloud and analytics tools.

BRIEF-Nice Reports Q1 Non-GAAP Earnings Per Share Of $1.03

* NICE REPORTS 10% REVENUE GROWTH FOR THE FIRST QUARTER 2018 ALONG WITH 32% GROWTH IN CLOUD REVENUE

BRIEF-NICE To Acquire Mattersight, Bolstering Its Leadership In Cloud Customer Service Analytics

* NICE TO ACQUIRE MATTERSIGHT, BOLSTERING ITS LEADERSHIP IN CLOUD CUSTOMER SERVICE ANALYTICS

BRIEF-NICE Q4 Earnings Per Share $1.27

* NICE REPORTS STRONG FINISH TO 2017 WITH 31% GROWTH IN ANNUAL REVENUE AND 14% GROWTH IN ANNUAL EPS

Israel's Nice Q4 profit tops estimates, sees strong 2018

Israeli software provider Nice posted better-than-expected fourth-quarter profit on record revenue and forecast strong growth in 2018, boosted by its analytic and cloud tools.

Israel's Nice tops Q3 estimates, tweaks 2017 profit forecast

Israeli software provider Nice narrowed the range of its 2017 earnings estimate after topping third-quarter forecasts boosted by higher revenue in its omni-channel, cloud, analytics and artificial intelligence businesses.

BRIEF-Nice Ltd reports Q3 earnings per share of $0.42

* Q3 2017 total revenues increased 36.1% to $322.8 million compared to $237.2 million for Q3 of 2016

UK's NICE gives Roche drug green light for bladder cancer

Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.

BRIEF-Migdal Insurance & Financial Holdings reports 4.95 pct passive stake ​ in Nice as of Oct 26

* Migdal Insurance & Financial Holdings Ltd reports 4.95 percent passive stake in Nice Ltd as of Oct 26 - SEC filing Source text: (http://bit.ly/2lxaLhu) Further company coverage:

UK finds Roche bladder cancer drug too costly for routine use

Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.

NICE backs first-line use of Merck's Keytruda under cancer fund

Britain's cost-effectiveness agency NICE has decided that Merck & Co's immunotherapy drug Keytruda can be used in previously untreated lung cancer patients under special funding arrangements.

BRIEF-Nice reports 35 pct growth in Q1 revenue

* Nice reports 35 pct growth in revenue for the first quarter 2017

BRIEF-Nice Ltd says selected for San Francisco Dept Of Emergency Management's 9-1-1 center upgrade

* Nice Ltd - San Francisco Department Of Emergency Management selects Nice for 9-1-1 center upgrade Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up